Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price traded up 22.4% on Friday . The stock traded as high as $0.41 and last traded at $0.40. 60,477,578 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 79,476,109 shares. The stock had previously closed at $0.33.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research note on Friday, January 17th. They set a "hold" rating on the stock.
View Our Latest Stock Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Stock Up 17.0 %
The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock has a 50 day simple moving average of $0.28 and a 200 day simple moving average of $0.28. The stock has a market cap of $71.60 million, a price-to-earnings ratio of -0.01 and a beta of 2.02.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. As a group, analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tonix Pharmaceuticals
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
